Endocare to Acquire Cryosurgical Company

In a move to strengthen its position in the prostate cryoablation market, Endocare, Inc. (Irvine, CA, USA) has agreed to acquire the cryosurgical business and assets of Cryomedical Sciences, Inc. (CMS, Kennesaw, GA, USA) for US$2.2 million in cash and stock.

Endocare will assume ownership of all the cryosurgical assets of CMS, consisting of an installed base of more than 100 devices, regulatory approvals, and intellectual property that includes 12 issued and pending patents. CMS markets the CMS AccuProbe system and single-use CMS cryoprobes, which are used to ablate benign or malignant tissue in minimally invasive procedures. The AccuProbe system incorporates patented technology that supercools liquid nitrogen and maintains the nitrogen in a liquid state for optimal cell destruction.

Endocare has developed products for the treatment of prostate cancer and benign prostate hyperplasia (BPH). In February, the company acquired Timm Medical Technologies, Inc., which also makes urology products, including an office-based treatment for BPH.
Endocare's chairman and CEO, Paul Mikus, noted, "CMS has an active installed base that we can build upon by offering the advantage of our Cryocare technology and the benefits of our physician and patient support organization.”




Related Links:
Endocare
Cryomedical Sciences, Inc.